Multidose risperidone treatment evaluated in a rodent model of tardive dyskinesia

Neuropsychopharmacology

Volumn 31, Issue 9, 2006, Pages 1864-1868

  Gao, Xue Min ^a   Cooper, Thomas ^b   Suckow, Raymond F ^b   Tamminga, Carol A ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b NATHAN S KLINE INSTITUTE FOR PSYCHIATRIC RESEARCH   (United States)

Author keywords

5HT2A receptor; Antipsychotic; Haloperidol; Tardive dyskinesis; Vacuous chewing movement

Indexed keywords

PLACEBO; RISPERIDONE;

AKATHISIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG EFFECT; IMMEDIATE EARLY GENE; LOW DRUG DOSE; MOTOR ACTIVITY; MULTIPLE DRUG DOSE; NONHUMAN; PARKINSONISM; PREDICTION; PRIORITY JOURNAL; RAT; TARDIVE DYSKINESIA;

ANIMALS; ANTIPSYCHOTIC AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DYSKINESIA, DRUG-INDUCED; HALOPERIDOL; MALE; RATS; RATS, SPRAGUE-DAWLEY; RISPERIDONE; STEREOTYPED BEHAVIOR;

EID: 33747356492     PISSN: 0893133X     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.npp.1300975     Document Type: Article

References (38)

1. Andreassen OA, Ferrante RJ, Aamo TO, Beal MF, Jorgensen HA (2003). Oral dyskinesias and histopathological alterations in substantia nigra after long-term haloperidol treatment of old rats. Neuroscience 122: 717-725.
2. Bianchetti G, Morselli PI (1978). Rapid and sensitive method for determination of haloperidol in human samples using nitrogen-phosphorous selection detection. J Chromatogr 153: 203-210.
3. Chouinard G, Jones B, Remington G, Bloom D, Addington D, MacEwan GW et al (1993). A Canadian multicenter placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients [published erratum appears in J Clin Psychopharmacol 1993 Apr; 13(2):149] [see comments]. J Clin Psychopharmacol 13: 25-40.
4. Clow A, Jenner P, Theodorou A, Marsden CD (1980a). Changes in cerebral dopamine metabolism and receptors during one-year neuroleptic administration and subsequent withdrawal: relevance to brain biochemistry in schizophrenia (Review). Adv Biochem Psychopharmacol 24: 53-55.
5. Clow A, Theodorou A, Jenner P, Marsden CD (1980b). Cerebral dopamine function in rats following withdrawal from one year of continuous neuroleptic administration. Eur J Pharmacol 63: 145-157.
6. Clow A, Theodorou A, Jenner P, Marsden CD (1980c). Changes in cerebral dopamine function induced by a year's administration of trifluoperazine or thioridazine and their subsequent withdrawal. Adv Biochem Psychopharmacol 24: 335-340.
7. Conley RR, Mahmoud R (2001). A randomized double-blind study of risperidone and olanzapine in the treatment of schizophrenia or schizoaffective disorder. Am J Psychiatry 158: 765-774.
8. Correll CU, Leucht S, Kane JM (2004). Lower risk for tardive dyskinesia associated with second-generation antipsychotics: a systematic review of 1-year studies. Am J Psychiatry 161: 414-425.
9. Ellison G, See R, Levin E, Kinney J (1987). Tremorous mouth movements in rats administered chronic neuroleptics. Psychopharmacology 92: 122-126.
10. Farde L, Wiesel FA, Halldin C, Sedvall G (1988). Central D2-dopamine receptor occupancy in schizophrenic patients treated with antipsychotic drugs. Arch Gen Psychiatry 45: 71-76.
11. Gao XM, Hashimoto T, Cooper TB, Tamminga CA (1997). The dose-response characteristics of rat oral dyskinesias with chronic haloperidol or clozapine administration. J Neural Transm 104: 97-104.
12. Gao XM, Sakai K, Tamminga CA (1998). Chronic olanzapine or sertindole treatment results in reduced oral chewing movements in rats compared to haloperidol. Neuropsychopharmacology 19: 428-433.
13. Glenthoj B, Hemmingsen R (1989). Intermittent neuroleptic treatment induces long-lasting abnormal mouthing in the rat. Eur J Pharmacol 164: 393-396.
14. Gunne LM, Andersson U, Bondesson U, Johansson P (1986). Spontaneous chewing movements in rats during acute and chronic antipsychotic drug administration. Pharmacol Biochem Behav 25: 897-901.
15. Gunne LM, Growdon J, Glaeser B (1982). Oral dyskinesia in rats following brain lesions and neuroleptic drug administration. Psychopharmacology 77: 134-139.
16. Hashimoto T, Ross DE, Gao XM, Medoff DR, Tamminga CA (1998). Mixture in the distribution of haloperidol-induced oral dyskinesias in the rat supports an animal model of tardive dyskinesia. Psychopharmacology (Berl) 137: 107-112.
17. Ikeda H, Adachi K, Hasegawa M, Sato M, Hirose N, Koshikawa N et al (1999). Effects of chronic haloperidol and clozapine on vacuous chewing and dopamine-mediated jaw movements in rats: evaluation of a revised animal model of tardive dyskinesia. J Neural Transm 106: 1205-1216.
18. Janssen PA, Niemegeers CJ, Awouters F, Schellekens KH, Megens AA, Meert TF (1988). Pharmacology of risperidone (R 64 766), a new antipsychotic with serotonin-S2 and dopamine-D2 antagonistic properties. J Pharmacol Exp Therapeut 244: 685-693.
19. Jeste DV, Lacro JP, Bailey A, Rockwell E, Harris MJ, Caligiuri MP (1999). Lower incidence of tardive dyskinesia with risperidone compared with haloperidol in older patients. J Am Geriatr Soc 47: 716-719.
20. Kane JM, Smith JM (1982). Tardive dyskinesia: prevalence and risk factors 1959-1979. Arch Gen Psychiatry 39: 473-481.
21. Kane JM, Woerner M, Borenstein M, Wegner J, Liberman J (1986). Integrating incidence and prevalence of tardive dyskinesia. Psychopharmacol Bull 22: 254-258.
22. Kapur S, Remington G, Zipursky RB, Wilson AA, Houle S (1995). Dopamine receptor occupancy of risperidone and its relationship to extrapyramidal symptoms: a PET study. Life Sci 57: PL103-PL107.
23. Kapur S, VanderSpek SC, Brownlee BA, Nobrega JN (2003). Antipsychotic dosing in preclinical models is often unrepresentative of the clinical condition: a suggested solution based on in vivo occupancy. J Pharmacol Exp Ther 305: 625-631.
24. Leysen JE, Janssen PM, Megens AA, Schotte A (1994). Risperidone: a novel antipsychotic with balanced serotonin-dopamine antagonism, receptor occupancy profile, and pharmacologic activity. J Clin Psychiatry 55(Suppl): 5-12.
25. 2 receptors. Psychopharmacology 112: S40-S54.
26. Marchese G, Bartholini F, Casu MA, Ruiu S, Casti P, Congeddu E et al (2004). Haloperidol versus risperidone on rat 'early onset' vacuous chewing. Behav Brain Res 149: 9-16.
27. Marder SR, Meibach RC (1994). Risperidone in the treatment of schizophrenia. Am J Psychiatry 151: 825-835.
28. McKinney WT, Bunney WE (1969). Animal models of depression. Arch Gen Psychiatry 21: 240-248.
29. Megens AA, Awouters F, Schotte A, Meert TF, Dugovic C, Niemegeers CJ et al (1994). Survey on the pharmacodynamics of the new antipsychotic risperidone. Psychopharmacology 114: 9-23.
30. Robertson GS, Matsumura H, Fibiger HC (1994). Induction patterns of Fos-like immunoreactivity in the forebrain as predictors of atypical antipsychotic activity. J Pharmacol Exp Therapeut 271: 1058-1066.
31. Sakai K, Gao XM, Tamminga CA (2001). Scopolamine fails to diminish chronic haloperidol-induced purposeless chewing in rats. Psychopharmacology (Berl) 153: 191-195.
32. Shirakawa O, Tamminga CA (1994). Basal ganglia GABAA and dopamine D1 binding site correlates of haloperidol-induced oral dyskinesias in rat. Exp Neurol 127: 62-69.
33. Tamminga C, Woerner MG (2002). Clinical course and cellular pathology of tardive dyskinesia. In: Davis KL, Charney DS, Coyle JT, Nemeroff CB (eds). Neuropsychopharmacology: The Fifth Generation of Progress. American College of Neuropsychopharmacology. Lippincott Williams & Wilkins: Philadelphia. pp 1832-1842.
34. Tamminga CA, Dale JM, Goodman L, Kaneda H, Kaneda N (1990). Neuroleptic-induced vacuous chewing movements as an animal model of tardive dyskinesia: a study in three rat strains. Psychopharmacology 102: 474-478.
35. Trevitt JT, Carlson BB, Salamone JD (1999). Behavioral assessment of atypical antipsychotics in rats: studies of the effects of olanzapine (Zyprexa). Psychopharmacology (Berl) 145: 309-316.
36. Waddington JL (1990). Spontaneous orofacial movements induced in rodents by very long-term neuroleptic drug administration: phenomenology, pathophysiology and putative relationship to tardive dyskinesia. Psychopharmacology 101: 431-447.
37. Weiss JM, Kilts CD (1995). Animal models of depression and schizophrenia. In: Schatzberg AF, Nemeroff CV (eds). Textbook of Psychopharmacology. American Psychiatric Press: Washington, DC. pp 81-123.
38. Woestenborghs R, Lorreyne W, Van Rompaey F, Heykants J (1992). Determination of risperidone and 9-hydroxyrisperidone in plasma, urine and animal tissues by high-performance liquid chromatography. J Chromatogr 583: 223-230.